{image_1} Minnesota Oncology is pleased to introduce a new Director of Pharmacy Services, Paul Forsberg, PharmD, BCOP, MHA. Forsberg joined the practice in early October following the retirement of Jan Merriman, RPh, BCOP, after her nearly 20 years of pharmacy leadership at Minnesota Oncology.
Dr. Forsberg earned his PharmD degree from the University of Montana and received his Board Certification in Oncology Pharmacy (BCOP) in 2011. Earlier this year, Paul completed his Masters in Health Administration (MHA) degree from the University of Minnesota. For the past 4 years, Forsberg served as the Clinical Pharmacy Manager at St. John's Hospital in Maplewood, MN.
“Paul has great experience in Twin Cities in providing oncology pharmacy leadership services,” said Dean Gesme, MD, president of Minnesota Oncology. “Previously he has worked in a major health system as part of a clinical team to develop chemotherapy treatment plans, as well as medication related policies and procedures. We are fortunate to have his leadership in the ever-evolving oncology and hematology pharmacy services.”
Forsberg is the Vice President of the Upper Midwest Oncology Education Network and a current member of the Hematology/Oncology Pharmacy Association. He will serve on various councils at Minnesota Oncology, including the Co-Chair of the Pharmacy and Therapeutics Committee and the Co-Chair of the Clinical Practice Committee.
Share
Categories
Tags
Recent Posts
Clinical trials are essential to advancing cancer care. Learn what clinical trials are, how they work, and how they help improve treatment options for patients.
“Minnesota Oncology listens. You are heard. Any concern you have, they do their best to answer it,” she said. “I am so thankful for everyone at Minnesota Oncology – Dr. Vera, Syndey, the schedulers, infusion nurses, everyone at the Maple Grove clinic. You feel at home there, which is hard to do when you are going through treatment. Minnesota Oncology treats you like family.”
Testicular cancer happens when cancer cells grow in one or both testicles. It is not very common. About 1 in 250 men will get testicular cancer during their lifetime.